Nasdaq News

FedEx Corp suspended its 2020 profit outlook on Tuesday, citing uncertainty due to the coronavirus pandemic.

What happened Shares of several biotechs jumped on Tuesday as the overall stock market rebounded from a major downturn yesterday on reports that a huge federal stimulus package could be in the works. Biogen (NASDAQ: BIIB) stock was up 9.3% as of 3:13 p.m. EDT. Shares of GW Pharm

Anxiety over the coronavirus pandemic and its financial fallout can feel paralyzing. But a quote often attributed to tennis great Arthur Ashe offers a path forward: “Start where you are.…

U.S. stocks rose 6% on Tuesday, a day after their steepest declines since the 1987 crash, as the Federal Reserve took further steps to boost liquidity and stem damage from the coronavirus pandemic that has gripped the global economy and markets.

Disclaimer: I’m not a medical or epidemiological expert. All of these opinions are based on my own travel preferences and risk tolerance. They are not recommendations. As a travel writer…

Impossible Foods is discussing a new credit line worth several hundred million dollars with its lenders, as the plant-based meat company braces for the economic fallout of the coronavirus outbreak, people familiar with the matter said on Tuesday.

Image source: The Motley Fool.

But borrowers shouldn't celebrate just yet.

What happened Shares of General Motors (NYSE: GM) were falling in trading on Tuesday afternoon as investors considered the possibility that GM may need to shut down its U.S. factories for an extended period due to the coronavirus outbreak. Concerns about U.S. relations with Chin

What happened Shares of Peloton Interactive (NASDAQ: PTON) were gaining today, jumping after the stock got a bullish note from an analyst and rose for the second day on a row on the perception that lockdown-style conditions will be a boon for its business.

Bitcoin mixing, the practice of scrambling one’s bitcoin with others in order to obscure the connection between an individual’s identity and coin address information, has seen a number of innovations over the last decade. Some of the early mixing efforts took the simple for

The Renaissance International IPO Index (Ticker: IPOXUS), the underlying index for the Renaissance International IPO ETF (Ticker: IPOS), will implement the following constituent changes at the market's close on Friday, March 20, 2019:Additions: Pharmaron Beijing Poly Pr

(RTTNews) - Bargain hunting after previous session's setback, and positive reaction to various stimulus measures announced by global central banks and governments pushed up stock prices in the Switzerland market on Tuesday.

The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s close on Friday, March 20, 2019:Additions: OneConnect Financial Technology PPD

Luxury jeweler Tiffany & Co said on Tuesday it would temporarily close several stores, including its Fifth Avenue flagship store in New York, and reduce working hours at other outlets, in an effort to contain the spread of the novel coronavirus.

Top Health Care Stocks

In trading on Tuesday, shares of Royal Bank of Canada (Montreal, Quebec)'s Non-Cumulative First Preferred Shares Series AC (TSX: RY-PRC.TO) were yielding above the 5% mark based on its quarterly dividend (annualized to $1.15), with shares changing hands as low as $22.55 on the

Terry Booth, the founder and one-time CEO of Aurora Cannabis (ACB), has just sold 12.2 million shares of the company he once ran -- a development, says Jefferies analyst Owen Bennett, that is "not great for sentiment" about the stock.

You don't say!

As Aurora announced in a press release Monday, "Terry Booth has filed a report on the System for Electronic Disclosure by Insiders (SEDI) regarding his sale of approximately 12,161,900 shares into the open market ... in connection with the previously announced transition of Mr. Booth's role within the Company." The transition in question being, of course, Booth's resignation as CEO announced last month.

Why is Booth selling now? One might imagine that, because Booth is leaving the company, he'd want to cut ties with Aurora entirely, and is therefore selling off his stake in order to make as clean a cut as possible. But as Bennett points out, Booth "remains in a strategic advisor role" at the company. He has not in fact cut ties entirely. Moreover, as an important advisor to Aurora Cannabis, he presumably has a good insider's vantage point to how things are going within Aurora, and what the company's prospects look like.

In Bennett's estimation, Monday's stock sale suggests that Booth may see "some more difficult times ahead."

Which is not to say that the times behind Aurora have been all unicorns and rainbows. Indeed, a chart of Aurora Cannabis's fortunes over the past 12 months shows an almost straight line down from the top left axes to the bottom right, as Aurora Cannabis stock has sunk from a share price of nearly $10 a year ago, to $0.70 today -- a decline of 93%.

Most recently, Bennett notes, the company has lost its Chief Corporate Officer (Cam Battley, who resigned in December), followed by an announcement of a restructuring plan, including new "ambitious profitability targets" that no one seems to have much faith in.

Fact is, most analyst estimates still don't see Aurora turning GAAP profitable before 2023 at the earliest -- and the way things are going, the company may not make it that long. At last report, Aurora Cannabis was deeply unprofitable ($1.1 billion lost last year), burning cash (about $610 million burnt last year), and mired in debt (nearly $350 million in long term debt, against cash reserves of only about $140 million).

Sure, to hear management tell it, Aurora remains "the Canadian company defining the future of cannabis worldwide." Executive Chairman and Interim CEO Michael Singer still insists, "the Board and management remain focused on the plan we laid out in February and we are progressing as planned toward appropriate capital allocation, balance sheet strength, and profitability." And even Booth says he's only selling because "market volatility with respect to COVID-19 and a number of opportunities in the industry led to me taking some cash to the sidelines ... I believe many cannabis stocks including Aurora are undervalued and I will be watching present market conditions unfold. I will definitely be considering buying back in once the dust settles."

Regardless, actions speak louder than words. Investors owning the stock today, and seeing its founder dumping his shares  -- even with an expressed intention of perhaps buying back later -- might now be thinking to themselves "maybe we should think about buying back later, too, but for now -- sell!"

Turning now to the rest of the Street, it appears that other analysts are generally on the same page. With 12 Holds, 4 Sells, and just single Buy, the consensus rating comes in as a Hold. The average price target among these analysts stands at $1.87, which is about 165% higher than ACB's current value -- most likely a result of the quick drop and analysts’ inability to turnaround new price targets so quickly. (See Aurora Cannabis stock analysis on TipRanks)

To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Image source: The Motley Fool.